Low libido in both men and women involves impaired central dopamine/melanocortin signaling driving sexual motivation, reduced sex hormone levels (testosterone, estrogen), vascular insufficiency in genital tissue, and psychological factors including stress and depression. Peptide research addresses all four components for comprehensive libido restoration.
1. PT-141 (Bremelanotide) — Central Libido Activation
PT-141 directly activates melanocortin receptors (MC3R/MC4R) in the hypothalamus — the brain region governing sexual motivation and arousal. Unlike testosterone or other hormone approaches, PT-141 works centrally at the source of sexual desire, producing rapid and reliable libido enhancement regardless of hormonal status.
Dosing Protocol: 0.5–2 mg SubQ 45–90 min before sexual activity. Start at 0.5 mg to assess tolerance (nausea, facial flushing at higher doses). Use as needed, not daily.
2. Kisspeptin — Testosterone / Estrogen Axis Restoration
Kisspeptin is the master hypothalamic regulator of GnRH secretion and downstream sex hormone production. Low kisspeptin activity — increasingly common with age, obesity, and stress — suppresses LH pulsatility and testosterone/estrogen production. Kisspeptin administration directly restores sex hormone output and also has independent pro-sexual effects via limbic kisspeptin receptors.
Dosing Protocol: 50–100 mcg SubQ 2–3x per week. Effects on LH and sex hormones accumulate over 4–8 weeks of consistent use.
3. BPC-157 — Vascular / Dopamine Support
BPC-157 supports the dopaminergic and serotonergic circuits governing sexual motivation and mood, and promotes vascular health in genital tissue — ensuring adequate blood flow for physical arousal. It also addresses gut-brain axis dysregulation that can suppress libido through elevated stress hormone output.
Dosing Protocol: 250–500 mcg SubQ daily. Cycle: 6–8 weeks.
4. Ipamorelin + CJC-1295 — Hormonal Optimization Foundation
Optimizing GH pulsatility via Ipamorelin/CJC improves body composition (reducing the visceral fat that converts testosterone to estrogen), enhances sleep quality, and supports the metabolic environment in which healthy sex hormone levels are maintained. Low GH status is a frequently overlooked contributor to declining libido.
Dosing Protocol: 200–300 mcg Ipamorelin + 100–200 mcg CJC-1295 SubQ before bed. 5 on/2 off. Cycle: 12 weeks.
PT-141 is the direct libido switch — activating the central brain circuits of sexual desire immediately. Kisspeptin restores the hormonal production infrastructure when gonadal axis suppression is the underlying cause. BPC-157 supports the vascular and neurotransmitter systems enabling physical arousal. Ipamorelin/CJC provides the metabolic and hormonal foundation that determines baseline libido levels over time.
Research Use Only. All information on this page is for educational purposes only and is not medical advice. PepSherpa does not sell peptides. Consult a licensed healthcare provider before making any health decisions. Many of the studies cited are preclinical (animal/in-vitro).